Habig Gregory, Smaltz Christa, Halegoua-DeMarzio Dina
Department of Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Department of Medicine, Division of Gastroenterology and Hepatology, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Metabolites. 2021 Apr 15;11(4):242. doi: 10.3390/metabo11040242.
Sarcopenia, defined as the loss of muscle strength, mass, and functionality, confers a poor prognosis in the setting of cirrhosis. Given its clinical significance, a better understanding of the underlying mechanisms leading to cirrhosis, sarcopenia, and their co-occurrence may improve these patients' outcomes. Non-alcoholic steatohepatitis (NASH) shares many of the same etiologies as sarcopenia, including insulin resistance, chronic inflammation, and ectopic adipocyte deposition, which are hallmarks of metabolic syndrome (MS). NASH thus serves as a prime candidate for further exploration into the underlying pathophysiology and relationship between these three conditions. In this review, we discuss the natural history of NASH and sarcopenia, explore the interplay between these conditions in the scope of MS, and seek to better define how an assessment of muscle mass, strength, and functionality in this population is key to improved diagnosis and management of patients with sarcopenia and NASH.
肌肉减少症被定义为肌肉力量、质量和功能的丧失，在肝硬化患者中预后较差。鉴于其临床意义，更好地理解导致肝硬化、肌肉减少症及其同时发生的潜在机制可能会改善这些患者的预后。非酒精性脂肪性肝炎（NASH）与肌肉减少症有许多相同的病因，包括胰岛素抵抗、慢性炎症和异位脂肪细胞沉积，这些都是代谢综合征（MS）的特征。因此，NASH是进一步探索这三种情况的潜在病理生理学及其关系的主要候选对象。在这篇综述中，我们讨论了NASH和肌肉减少症的自然病史，探讨了这些情况在MS范围内的相互作用，并试图更好地确定如何评估该人群的肌肉质量、力量和功能对于改善肌肉减少症和NASH患者的诊断和管理至关重要。
